Kassi Filkins

Verana Health’s newly launched Qdata Cataract offers a comprehensive dataset to improve outcomes, reduce complications and enhance IOL technology.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

Topcon Healthcare appoints Daniela Ferrara, MD, PhD, as Chief Medical Officer to enhance AI-driven ocular imaging and advance digital healthcare solutions.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss the current status of eye stroke evaluations for CRAO.

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

On this part two episode with Colin Carr, founder and CEO of CARR, we hear more about commercial real estate dos and don'ts when managing the space of your practice. Tune in now for the Q&A with Ophthalmology Times® executive editor, David Hutton.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

Colin Carr, founder and CEO of CARR, chats with Ophthalmology Times' David Hutton in this part one episode of the EyePod. Carr hits on some hot real estate topics in the healthcare industry, including top mistakes healthcare providers make with their office space, how to decide whether you're going to purchase or lease, and how healthcare providers can save $100k or more on their next lease renewal.

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.

Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.

Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.

Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.

Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.

Alex Dastgheib, MD, ABO, discusses the findings of the paper, "325 Cases of Phacoemulsification in Blind Cataracts," presented at the 2022 ASCRS conference in Washington, DC. The paper won the Challenging Cases session during the meeting.

Jonathan Solomon, MD, shares his personal experience using the Beyeonics One exoscope, highlighting what makes this tool stand out.

Edward Hu, MD, PhD, looked at 812 toric IOLs utilized of various platforms, concluding a low total toric rotation rate at 2.1%.

Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.

Allie Holmes, head of US marketing for Johnson & Johnson Surgical Vision, shares an update on what visioning the company is doing with their new and elevated technologies.